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Abstract  Alcoholic  hepatitis  is  a  frequent  condition  in  the  Mexican  population.  It  is  cha-
racterized by  acute-on-chronic  liver  failure,  important  systemic  inflammatory  response,  and
multiple organ  failure.  The  severe  variant  of  the  disease  implies  elevated  mortality.  Therefore,
the Asociación  Mexicana  de  Gastroenterología  and  the  Asociación  Mexicana  de  Hepatologíadiscriminant  function
score; brought together  a  multidisciplinary  team  of  health  professionals  to  formulate  the  first Please cite this article as: Velarde-Ruiz Velasco JA, Higuera-de la Tijera MF, Castro-Narro GE, et al. Consenso Mexicano de hepatitis
lcohólica. Revista de Gastroenterología de México. 2020. https://doi.org/10.1016/j.rgmx.2020.04.002
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Mexican  consensus  on  alcoholic  hepatitis,  carried  out  utilizing  the  Delphi  method  and  resulting
in 37  recommendations.  Alcohol-related  liver  disease  covers  a  broad  spectrum  of  patholo-
gies that  includes  steatosis,  steatohepatitis,  different  grades  of  fibrosis,  and  cirrhosis  and  its
complications.  Severe  alcoholic  hepatitis  is  defined  by  a  modified  Maddrey’s  discriminant  func-
tion score  ≥  32  or  by  a  Model  for  End-Stage  Liver  Disease  (MELD)  score  equal  to  or  above  21.
There is  currently  no  specific  biomarker  for  its  diagnosis.  Leukocytosis  with  neutrophilia,  hyper-
bilirubinemia  (>3  mg/dl),  AST  >  50  U/l  (<  400  U/l),  and  an  AST/ALT  ratio  >  1.5-2  can  guide  the
diagnosis. Abstinence  from  alcohol,  together  with  nutritional  support,  is  the  cornerstone  of
treatment.  Steroids  are  indicated  for  severe  disease  and  have  been  effective  in  reducing  the
28-day mortality  rate.  At  present,  liver  transplantation  is  the  only  life-saving  option  for  patients
that are  nonresponders  to  steroids.  Certain  drugs,  such  as  N-acetylcysteine,  granulocyte-colony
stimulating  factor,  and  metadoxine,  can  be  adjuvant  therapies  with  a  positive  impact  on  patient
survival.
© 2020  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Published  by  Masson  Doyma  Me´xico  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Consenso  Mexicano  de  hepatitis  alcohólica
Resumen  La  hepatitis  alcohólica  es  una  condición  frecuente  en  población  mexicana,  se
caracteriza  por  insuficiencia  hepática  aguda  sobre  crónica,  importante  reacción  inflamatoria
sistémica y  fallo  multiorgánico,  que  en  la  variante  grave  de  la  enfermedad  implica  una  elevada
mortalidad.  Por  lo  anterior,  la  Asociación  Mexicana  de  Gastroenterología  y  la  Asociación  Mexi-
cana de  Hepatología  conjuntaron  un  equipo  multidisciplinario  de  profesionales  de  la  salud  para
elaborar el  primer  consenso  mexicano  de  hepatitis  alcohólica.  El  consenso  fue  elaborado  con
la metodología  Delphi,  emitiendo  37  recomendaciones.  La  enfermedad  hepática  relacionada  al
consumo  de  alcohol  comprende  un  amplio  espectro,  que  incluye  esteatosis,  esteatohepatitis,
fibrosis en  diferentes  grados,  cirrosis  y  sus  complicaciones.  La  hepatitis  alcohólica  grave  se
define por  una  función  modificada  de  Maddrey  ≥32  o  por  un  puntaje  de  MELD  (Model  for  End-
Stage Liver  Disease)  igual  o  mayor  a  21.  Actualmente  no  existe  un  biomarcador  específico  para
el diagnóstico.  La  presencia  de  leucocitosis  con  neutrofilia,  hiperbilirrubinemia  (>3  mg/dL),
AST >  50  U/L  (<400  U/L),  relación  AST/ALT  >  1.5-2  pueden  orientar  al  diagnóstico.  La  piedra
angular del  tratamiento  es  la  abstiencia  junto  con  el  soporte  nutricional.  Los  esteroides  estan
indicados en  la  forma  grave,  en  donde  han  resultado  efectivos  para  reducir  la  mortalidad  a  28
días. El  trasplante  hepático  es  en  la  actualidad  la  única  opción  con  que  se  cuenta  para  salvar  la
vida de  pacientes  no  respondedores  a  esteroides.  Ciertos  fármacos,  como  la  N-acetilcisteína,
el factor  estimulante  de  colonias  de  granulocitos,  y  la  metadoxina  pueden  ser  una  terapia
adyuvante que  puede  impactar  en  la  sobrevida  de  los  pacientes.
© 2020  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Publicado  por  Masson  Doyma  Me´xico  S.A.
Este es  un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Half  of  the  deaths  due  to  cirrhosis  of  the  liver  are  related  to
alcohol  consumption  worldwide.  In  Mexico,  alcohol-related
cirrhosis  of  the  liver  is  the  cause  of  approximately  50%  of  the
cases  of  cirrhosis  and  is  a  public  health  problem  with  a  direct
impact  on  an  elevated  mortality  rate  and  the  consequent
high  costs  for  the  health  system.  Alcoholic  hepatitis  (AH)  is
a  frequent  condition  in  the  Mexican  population  that  is  usu-
ally  characterized  by  acute-on-chronic  liver  failure  (ACLF),
important  systemic  inflammatory  response,  and  multiple
organ  failure.  The  severe  variant  of  the  disease  implies  an
elevated  mortality  rate.  Therefore,  the  Asociación  Mexicana
c
n
ie  Gastroenterología  (AMG) and  the  Asociación  Mexicana
e  Hepatología  (AMH) brought  together  a  multidisciplinary
eam  of  healthcare  professionals  made  up  of  gastroenterol-
gists,  hepatologists,  and  clinical  researchers  in  the  field  to
ormulate  the  first  Mexican  consensus  on  alcoholic  hepati-
is,  to  have  a  document  with  recommendations  that  can  aid
he  entire  medical  community  that  provides  clinical  care  to
atients  with  AH.
The  primary  aim  of  the  present  consensus  was  to  formu-
ate  a  document  containing  descriptions  and  analyses  of  the
urrent  evidence  on  the  basic  concepts,  epidemiology,  diag-
osis,  and  treatment  of  AH,  with  a  focus  on  their  application
n  daily  clinical  practice  in  Mexico.
3 J.A.  Velarde-Ruiz  Velasco  et  al.
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Table  1  Grade  system  codes.  GRADE  system:  Classifi-
cation  of  the  quality  of  evidence  and  the  strength  of
recommendation.
Quality  of  evidence  Code
High  A
Moderate  B
Low C
Very low  D
[10pt]  Strength  of  recommendation  Code
Strong,  in  favor  of  the  intervention 1
Weak,  in  favor  of  the  intervention 2
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ethodology
n  November  of  2018,  the  AMH  and  AMG  made  a  collabo-
ation  agreement  to  produce  the  first  Mexican  consensus
n  AH.  The  Delphi  method  was  employed  to  develop
he  consensus.1 Two  coordinators  were  designated,  one
rom  the  AMH  (JAVRV)  and  one  from  the  AMG  (MFHT),
nd  23  experts  from  the  gastroenterology  and  hepatology
pecialties  were  invited  to  participate.  In  January  of  2019,
he  coordinators  (JAVRV  and  MFHT)  and  3  other  experts
RCO,  JMAL,  and  ESGJ)  carried  out  a  thorough  search  of
he  following  databases:  the  Cochrane  Central  Register  of
ontrolled  Trials  (CENTRAL),  MEDLINE  (PubMed),  EMBASE
Ovid),  LILACS,  CINAHL,  BioMed  Central,  and  the  World
ealth  Organization  International  Clinical  Trials  Registry
latform  (ICTRP).  The  search  encompassed  the  time  frame
f  January  1,  1990,  to  February  2019,  and  in  particular
ases  for  the  sections  on  basic  concepts  and  treatment,
overed  the  same  period  but  beginning  with  the  year
971.  All  articles  in  English  and  Spanish  were  included.
reference  was  given  to  consensuses,  guidelines,  systematic
eviews,  and  meta-analyses.  Complementary  electronic
nd  manual  searches  were  also  carried  out  in  the  archives
f  the  Revista  de  Gastroenterología  de  México  and  all
he  publications  that  the  coordinators  considered  relevant
p  to  February  2019.  The  search  criteria  included  the
erm  ‘‘alcoholic  hepatitis’’  combined  with  the  following
erms:  ‘‘epidemiology’’,  ‘‘incidence’’,  ‘‘prevalence’’,
‘Mexico’’,  ‘‘pathophysiology’’,  ‘‘mortality’’,  ‘‘diagnosis’’,
‘differential  diagnosis’’,  ‘‘treatment’’,  ‘‘antibiotics’’,
‘infection’’,  ‘‘therapy’’,  ‘‘management’’,  ‘‘steroids’’,
‘nutrition’’,  ‘‘review’’,  ‘‘guidelines’’,  ‘‘transplant’’,
‘meta-analysis’’,  and  their  Spanish  equivalents.  The  entire
ibliography  was  made  available  to  the  members  of  the
onsensus  through  a  virtual  library.
The  coordinators  then  formulated  36  statements,  which
nderwent  a  first  round  of  anonymous  electronic  voting
February  21  to  27,  2019)  to  evaluate  the  drafting  and
ontent  of  the  statements.  The  consensus  participants  emit-
ed  their  votes,  as  follows:  a)  in  complete  agreement,  b)
n  partial  agreement,  c)  uncertain,  d)  in  partial  disagree-
ent,  and  e)  in  complete  disagreement.  After  the  first  vote,
he  coordinators  made  the  corresponding  modifications.  The
tatements  that  reached  complete  agreement  in  >  75%  of
he  participants  were  kept  and  the  ones  that  had  complete
isagreement  in  >  75%  of  the  participants  were  eliminated.
he  statements  that  reached  ≤  75%  complete  agreement
nd  ≤  75%  complete  disagreement  were  reviewed  and  re-
tructured.  The  revised  statements  underwent  a second
ound  of  anonymous,  electronic  voting  (March  3  to  8,  2019).
ccording  to  the  comments  from  the  second  round  of  vot-
ng,  the  statements  were  revised  and  underwent  a  third
ound  of  voting  (March  9  to  15,  2019).  In  that  round,  along
ith  the  drafting  review,  the  strength  of  recommendation
nd  quality  of  evidence  for  sustaining  the  recommendation
ere  established,  utilizing  the  Grading  of  Recommendations
ssessment,  Development,  and  Evaluation  (GRADE)  system.2
n  the  GRADE  system,  the  quality  of  evidence  is  not  deter-
ined  solely  by  the  research  design  or  methodology,  but
lso  by  the  function  of  a  clearly  posed  question  related
n
s
m
bWeak,  against  the  intervention 2
Strong,  against  the  intervention  1
o  a  clearly  formulated  outcome  variable.3 Thus,  evidence
an  be  high,  moderate,  low,  or  very  low.  The  GRADE  sys-
em  also  establishes  the  strength  of  the  recommendations
s  strong  or  weak  and  in  favor  of  or  against  the  interven-
ion  or  statement.  Table  1  shows  the  codes  employed  in
he  GRADE  system:  upper  case  letters  classify  the  quality
f  evidence,  followed  by  a  number  indicating  the  strength
f  recommendation  in  favor  of  or  against  the  intervention
r  statement.
The  results  of  the  third  round  of  voting  were  presented
n  March  15  and  16,  2019,  at  a  face-to-face  meeting  held  in
nsenada,  Baja  California.  At  that  meeting,  the  statements
hat  reached  agreement  in  >  75%  of  the  participants  were
atified.  Those  that  did  not  reach  75%  agreement  in  the  pre-
ious  rounds  of  voting  were  discussed,  in  an  effort  to  reach
 consensus,  and  if  none  was  attained,  the  statements  were
liminated.  The  remaining  statements  under  consideration
ere  then  voted  on  again.
Once  all  the  consensus  statements  were  established,  the
oordinators  put  together  the  present  manuscript,  which
as  reviewed  and  approved  by  all  the  members  of  the
onsensus.
thical considerations
he  authors  of  the  present  work  declare  that  no  experiments
n  humans  or  animals  were  performed  for  its  formula-
ion,  and  there  were  no  confidentiality  conflicts,  given  that
o  patient  data  appear.  Because  no  data  from  persons  or
atients  were  utilized,  no  statements  of  informed  consent
ere  required.
esults
he  coordinators  initially  proposed  36  statements.  In  the
rst  voting  round,  one  statement  was  eliminated  due  to
ack  of  consensus.  The  second  voting  round  was  conducted
n  35  statements,  and  according  to  the  voting  results,  two
ew  statements  were  proposed,  resulting  in  a  total  of  37
tatements  for  the  third  round  of  voting.  In  the  face-to-face
eeting,  the  37  statements  were  presented,  31  (84%)  to
e  ratified  and  6  (16%)  to  be  voted  on  again.  At  the  end
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of  the  face-to-face  meeting,  once  several  statements  were
reviewed,  eliminated,  and  fused  together,  the  members  of
the  consensus  decided  on  37  statements,  classified  into  6
sections:
•  Basic  concepts  of  alcohol-related  liver  disease
•  Diagnostic  tests  for  the  detection  of  alcohol-related  liver
disease
•  Diagnosis  of  alcoholic  hepatitis
•  Evaluation  and  prognosis  of  patients  with  alcoholic  hep-
atitis
•  Treatment  of  fibrosis  due  to  alcohol-related  liver  disease
•  Treatment  of  alcoholic  hepatitis
The  final  statement  recommendations  and  voting  results
are  presented  below.
 BASIC  CONCEPTS  OF  ALCOHOL-RELATED  LIVER  DISEASE
1  Alcohol  use  disorder  is  defined  as  the  hazardous  and
harmful  consumption  of  alcohol  that  compromises  social,
family,  and  work  environments.  It  causes  clinically  signif-
icant  malaise  or  decline,  with  several  grades  of  severity,
depending  on  the  number  of  criteria  met.  The  term  alco-
holism  should  be  avoided,  given  that,  in  addition  to  not
being  clinically  useful,  the  social  stigmatization  it  implies
can  be  detrimental.
Agreement  reached:  100%  in  complete  agreement.
According  to  the  World  Health  Organization  (WHO),  50%
of  deaths  by  cirrhosis  worldwide  are  related  to  alcohol
consumption.4 In  2013,  more  than  23,000  persons  died
from  cirrhosis  in  Mexico,  and  almost  three-quarters  of
those  deaths  were  in  men.  Cirrhosis  of  the  liver  is  the
fourth  cause  of  loss  of  health  in  Mexico  and  accumulates
4.1%  of  the  disease  burden,  according  to  the  disability-
adjusted  life  year  (DALY)  indicator.  It  is  in  fifth  place,  with
respect  to  general  mortality,  and  as  a  cause  of  prema-
ture  death,  it  is  in  fourth  place.  Alcohol  predominates  in
men  as  the  cause  of  cirrhosis  in  the  Mexican  population,
whereas  hepatitis  C  is  the  most  common  cause  in  women.
Nationally,  46%  of  the  disease  burden  from  cirrhosis  is  asso-
ciated  with  alcohol  consumption  and  35%  with  hepatitis
C.5
The  fourth  edition  of  the  Diagnostic  and  Statistical
Manual  of  Mental  Disorders  (DSM-IV)  described  two  differ-
ent  alcohol-related  disorders:  alcohol  abuse  and  alcohol
dependence,  each  with  specific  criteria.6 The  DMS-5  inte-
grates  those  two  disorders  into  only  one,  currently  called
alcohol  use  disorder  (AUD),  and  it  is  classified  as  mild,
moderate,  or  severe.  According  to  the  DMS-5,  alcohol
use  disorder  is  diagnosed  when  two  or  more  of  the  11
criteria  described  in  the  manual  are  positive  (Table  2).
Alcohol  use  disorder  severity  is  based  on  the  number
of  positive  criteria:  mild  (2-3  positive  criteria),  moder-
ate  (4-5  positive  criteria),  and  severe  (6  or  more  positive
criteria).7
The  terms  alcoholism,  alcoholic,  and  alcohol  abuse  have
been  eliminated  and  are  no  longer  considered  appropri-
ate,  given  that  they  stigmatize  the  patient.  The  criterion
of  having  had  legal  problems  related  to  alcoholic  beverage
consumption  for  defining  alcohol  use  disorder  has  also  been
eliminated.8
i
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According  to  the  tenth  revision  of  the  International
tatistical  Classification  of  Diseases  and  Related  Health
roblems  (ICD-10),  when  alcohol  consumption  causes  phys-
cal  or  mental  damage  to  health,  it  is  considered  harmful
lcohol  use.9
 Alcohol-related  liver  disease  covers  a  broad  spectrum
of  pathologies  that  includes  steatosis,  steatohepati-
tis,  different  grades  of  fibrosis,  and  cirrhosis  and  its
complications.
Agreement  reached:  100%  in  complete  agreement.
Alcoholic  liver  disease  (ALD)  encompasses  different
rades  of  lesions  that  range  from  simple  steatosis  to  cir-
hosis.  They  may  not  necessarily  be  progressive  stages
f  the  disease  and  all  of  them  can  coexist  in  the  same
atient.10 Simple  steatosis,  initially  macrovesicular  and
ater  mixed  (macrovesicular  and  microvesicular),  is  the  ear-
iest  change  and  presents  in  90%  of  the  individuals  that
re  hazardous  drinkers11,12or  binge  drinkers 13 (see  the
efinition  of  terms  further  ahead).  However,  that  lesion
s  often  reversible,  with  sustained  alcohol  abstinence.14
lthough  the  prevalence  of  each  histologic  lesion  in  ALD  is
ot  precisely  known,15 25%  of  patients  with  ALD  are  esti-
ated  to  develop  steatohepatitis  and  close  to  15%  progress
o  cirrhosis.16--18 The  5-year  accumulated  risk  for  devel-
ping  hepatocellular  carcinoma  in  patients  with  cirrhosis
ue  to  alcohol  is  an  estimated  1%.19 The  hepatic  lesion
steatosis,  steatohepatitis,  and  fibrosis)  in  ALD  begins  by
ffecting  the  perivenular  hepatocytes,  then  progresses  to
he  mid-lobule  hepatocytes,  and  finally  affects  the  peripor-
al  hepatocytes.13
 Patients  with  alcohol-related  liver  disease  require  a
comprehensive  psychiatric  evaluation  and  concomitant
management  by  trained  addiction  personnel.
Agreement  reached:  100%  in  complete  agreement.
Alcohol  abstinence  is  crucial  in  all  patients  with  ALD  and
sychosocial  intervention  by  trained  personnel  is  an  essen-
ial  tool  for  achieving  abstinence  and  preventing  relapse  in
lcohol  consumption.20
Different  psychosocial  interventions  have  been  shown
o  be  effective  in  favoring  alcohol  abstinence.  Twelve-
tep  facilitation  (TSF)  therapy,21 motivational  enhancement
herapy  (MET),22 and  cognitive-behavioral  coping  skills
herapy23 are  three  interventions  that  have  demonstrated
qually  significant  and  sustained  improvement  for  achiev-
ng  abstinence  and  preventing  relapse  up  to  one  year  of
ollow-up.24
In  a  systematic  review,  Khan  A.  et  al.  included  13  stud-
es  (five  were  randomized  clinical  trials  and  the  others  were
bservational  studies)  with  a  total  of  1,945  patients.  They
valuated  the  effect  of  motivational  enhancement  therapy,
ognitive  behavioral  therapy  (CBT),  motivational  interview-
ng,  supportive  therapy,  and  psychoeducation.  Integrated
herapy  that  combined  CBT,  motivational  enhancement
herapy,  and  comprehensive  medical  care  were  found  to
ncrease  alcohol  abstinence.  Abstinence  was  not  maintained
ith  any  of  the  psychosocial  interventions,  but  relapse
ppeared  to  be  reduced  with  the  integrated  therapy  of  CBT
nd  medical  care.25
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Table  2  DSM-5  criteria  for  defining  alcohol  use  disorder.
1  Have  you  had  times  when  you  ended  up  drinking  more  or  for  a  longer  period  of  time  than  you  intended?
2  Have  you  wanted  more  than  once  to  cut  down  on  your  drinking  or  stop  it  altogether,  or  tried  to,  but  couldn’t?
3 Do  you  spend  a  lot  of  time  drinking  or  procuring  alcohol,  or  are  you  sick  much  of  the  time  due  to  drinking  or  to  getting  over  the  aftereffects?
4 Have  you  craved  a  drink  so  badly  that  you  couldn’t  think  about  anything  else?
5 Have  you  found  that  drinking,  or  being  sick  due  to  drinking,  often  interferes  with  taking  care  of  your  home  or  family?  Or  caused  problems  at  work?  Or  caused  academic
problems?
6 Have  you  continued  to  drink  even  though  it  was  causing  problems  with  your  family  or  friends?
7 Have  you  given  up  or  cut  back  on  activities  that  were  important  or  interesting  for  you  or  gave  you  pleasure,  in  order  to  drink?
8 Have  you  gotten  yourself  into  situations  more  than  once,  while  or  after  drinking,  that  increased  your  chances  of  getting  hurt  (such  as  driving,  swimming,  operating
machinery, walking  in  a  dangerous  area,  or  having  unsafe  sex)?
9 Have  you  continued  to  drink  even  though  it  makes  you  feel  depressed  or  anxious  or  has  led  to  your  having  some  other  health  problem,  or  becoming  forgetful,  or  having
memory loss,  or  blacking  out?
10 Have  you  had  to  drink  much  more  than  before  to  feel  the  desired  effect?  Or  found  that  the  usual  number  of  drinks  has  much  less  effect  than  before?
11 Have  you  found  that  when  the  effects  of  alcohol  were  wearing  off,  you  had  withdrawal  symptoms,  such  as  trouble  sleeping,  tremors,  restlessness,  nausea,  sweating,
tachycardia, or  convulsions?  Have  you  sensed  things  that  actually  were  not  there?
All the criteria should be asked in relation to the past 12 months.
The  Mexican  consensus  on  alcoholic  hepatitis  
Table  3  Types  of  standard  alcoholic  beverages  according
to the  NOM-142-SSA1/SCFI-2014  on  ‘‘Alcoholic  beverages.
Health  specifications.  Health  and  commercial  labeling’’.
Type  of  beverage  Alcoholic  volume
percentage  (%  abv)
Amount
in  mL
Beer  5  330  mL
Wine 12  140  mL
Fortified  wine  (e.g.,
sherry)
18  90  mL
Liqueur  or  aperitif  25  70  mL s
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6Distilled  spirits 40  40  mL
abv: content of alcohol by volume.
According  to  the  Mexican  2013-2018  Specific  Action
for  Addiction  Prevention  and  Comprehensive  Care  Pro-
gram,  the  identification  of  risk  groups  is  preponderant,  so
they  can  receive  interventions  in  line  with  their  necessi-
ties  and  conditions  of  risk.  For  those  that  present  with
use  or  abuse  of  tobacco,  alcohol,  and  other  drugs,  it
is  critical  to  offer  them  brief  interventions,  specialized
treatment,  rehabilitation,  and  support  for  their  social
reintegration.26
4  The  quantification  of  alcohol  intake  per  gram/day  can
be  calculated  through  the  formula:  gram/day  of  alco-
hol  = (quantity  ingested  in  milliliters)  (alcohol  content
of  the  ingested  beverage)  (0.8)/100.  As  an  alternative
for  standardizing  the  measurement  of  alcohol  consump-
tion,  a  proposed  standard  drink  is  equivalent  on  average
to  10-14  grams  of  alcohol.
Agreement  reached:  96%  in  complete  agreement;  4%  in
partial  agreement.
In  their  guidelines  on  brief  intervention  for  prevent-
ing  hazardous  and  harmful  alcohol  consumption,  the  WHO
defines  a  standard  drink  as  10  g  of  pure  ethanol  and
recommends  not  having  more  than  two  standard  drinks
per  day,  for  both  men  and  women.27 Importantly,  that
parameter  suggested  by  the  WHO  appears  to  be  the  most
appropriate,  given  that  it  is  the  simplest  and  easiest  to
replicate  in  clinical  practice  and  for  standardizing  clini-
cal  trials.28 However,  the  quantity  of  alcohol  in  a  standard
drink  varies,  according  to  continental  region,  and  dif-
fers  even  between  countries.  As  found  in  the  medical
literature,  amounts  of  alcohol  in  a  standard  drink  vary
from  8  g  (Iceland)  to  20  g  (Austria)  of  pure  ethanol.29
Regarding  Mexico,  the  Norma  Oficial  Mexicana  (NOM),
NOM-142-SSA1/SCFI-2014  on  ‘‘Alcoholic  beverages.  Health
specifications.  Health  and  commercial  labeling’’,  published
in  the  Diario  Oficial  de  la  Federación  (DOF) in  March  2015,
specifically  indicates  that  the  approximate  alcohol  content
in  a  ‘‘standard  drink’’  is  13  g,  considering  that  its  spe-
cific  gravity  is  0.785  g/mL.30 Table  3  shows  the  different
types  of  standard  alcoholic  beverages  and  their  composition,
according  to  that  established  in  the  NOM-142-SSA1/SCFI-
2014.
5 Alcohol  consumption  patterns  are  defined  as:  a)
‘‘hazardous  drinking’’,  more  than  three  standard  drinks337
per  day  for  men  (>  30  g/day)  and  more  than  two  standard
drinks  per  day  for  women  (>  20  g/day);  b)  ‘‘heavy  episodic
drinking’’,  six  or  more  standard  drinks  (≥  60  g  of  alcohol
on  at  least  one  occasion);  and  c)  ‘‘binge  drinking’’,  four
or  more  standard  drinks  for  women  (>  40  g  of  alcohol)  and
five  or  more  standard  drinks  for  men  (>  50  g  of  alcohol)  in
fewer  than  two  hours.
Agreement  reached:  100%  in  complete  agreement.
The  quantity  of  alcohol  consumed,  regardless  of  the  con-
umption  pattern,  is  the  most  important  risk  factor  for
eveloping  ALD.31 Epidemiologic  studies  have  shown  a  strong
orrelation  between  the  quantity  and  duration  of  alcohol
onsumption  and  the  presence  of  cirrhosis.32 In  a  cohort
hat  included  6,970  adults  from  the  general  population,
he  frequency  of  cirrhosis  was  significantly  higher  in  those
hat  consumed  ≥  30  g/day  of  alcohol,  compared  with  those
hat  were  abstinent  or  that  consumed  <  30  g/day  (2.2%  vs.
.08%).  The  subjects  that  registered  alcohol  consumption  >
20  g/day  had  the  highest  risk  for  presenting  with  cirrhosis
13.5%).33
Women  are  more  susceptible  to  liver  injury  from  alco-
ol  than  men.34,35 Some  studies  have  even  reported  that
omen  have  a  higher  risk  for  presenting  with  ALD,  con-
uming  half  the  alcohol  dose  considered  harmful  in  men.
ikewise,  women  have  a  higher  risk  for  accelerated  disease
rogression  and  risk  for  developing  cirrhosis  than  men.  One
tudy  showed  that  women  whose  alcohol  consumption  was
 100  g/day  developed  cirrhosis  in  a mean  length  of  time
f  13.5  years,  compared  with  a  mean  length  of  time  of
0  years  in  men.34 Women  with  alcohol  use  disorder  that
ngested  >  20  g/day  of  alcohol  had  a  higher  risk  for  develop-
ng  ALD.36
Alcohol  consumption  pattern,  especially  ‘‘heavy  episodic
rinking’’  and  ‘‘binge  drinking’’,  is  another  factor  that  has
een  proposed  in  experimental  models  as  a  possible  risk  fac-
or  for  developing  ALD.  Nevertheless,  at  present,  a  given
onsumption  pattern  has  not  been  clearly  related  to  a  higher
isk  for  ALD  in  humans,37 nor  has  an  association  been  demon-
trated  in  humans  between  the  type  of  alcoholic  beverage
r  the  quality  of  alcohol  consumed  and  the  development
f  severe  forms  of  the  disease,  such  as  alcoholic  hepatitis
AH).38
In  patients  with  comorbidities,  such  as  metabolic  syn-
rome,  or  chronic  hepatitis  B  or  hepatitis  C  virus  infection,
nd  alcohol  consumption,  even  in  quantities  below  those
onsidered  ‘‘hazardous  drinking’’,  can  favor  and  accelerate
rogression  to  liver  injury.39,40 Those  patients  should  avoid
lcohol  consumption.
Smoking  is  a condition  that  is  frequently  associated  with
lcohol  use.  There  is  a  three-times  higher  risk  for  developing
lcohol-related  cirrhosis  in  persons  that  smoke  one  or  more
acks  per  day,  compared  with  nonsmokers.41
 ‘‘Alcoholic  hepatitis’’  is  a  severe  condition  that  fre-
quently  behaves  as  ‘‘acute-on-chronic  liver  failure’’.  It
is  characterized  by  systemic  inflammation  and  a  predis-
position  to  the  development  of  infections,  kidney  failure,
encephalopathy,  and  multiple  organ  dysfunction,  with  an
elevated  mortality  rate  of  20-50%  in  the  following  three
months,  albeit  possibly  higher  in  the  Mexican  population.
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Agreement  reached:  100%  in  complete  agreement.
Hepatitis  or  steatohepatitis  due  to  alcohol  has  a  wide
linical  spectrum  that  ranges  from  an  asymptomatic  or  min-
mal  symptom  status  or  mild  clinical  signs  of  disease  to  the
resentation  of  severe  acute-on-chronic  liver  failure.42--44
evere  AH  is  defined  by  a  modified  Maddrey’s  discriminant
unction  (MDF)  score  ≥  32  or  a  Model  for  End-Stage  Liver
isease  (MELD)  score  equal  to  or  greater  than  21.42 Mortal-
ty  at  three  months  is  high,  but  variable,  depending  on  the
opulation  studied.  Sidhu  SS  et  al.  calculated  three-month
ortality  in  AH  at  between  30-70%.45 In  some  populations,
specially  European  ones,  the  general  mortality  rate  for  AH
s  low.  In  the  STeroids  Or  Pentoxifylline  for  Alcoholic  Hep-
titis  (STOPAH)  study,  mortality  at  28  days  varied  between
3.5%  and  19.4%.46
In  a  recent  systematic  review  that  included  77  stud-
es  published  between  1971  and  2016,  a  total  of  8,184
atients  were  analyzed,  finding  a  general  mortality  rate
ue  to  AH  at  28  days  of  26%,  at  90  days  of  29%,  and
t  180  days  of  44%.  Comparing  the  mortality  frequency
etween  the  different  decades,  there  were  no  significant
hanges  over  time;  not  at  28  days  or  at  90  days  (Pear-
on  correlation  coefficient  r  -0.216,  p  =  0.098;  and  r  0.121,
 =  0.503,  respectively).  A  small  but  significant  increase  was
bserved  in  relation  to  mortality  at  180  days  (r  0.461,
 =  0.036).47
In  Mexico,  a  multicenter  study  that  included  175  patients
t  four  different  hospitals,  found  that  121  (69%)  patients
ad  underlying  cirrhosis  and  125  (71%)  patients  developed
t  least  one  complication  during  hospitalization:  acute
idney  injury  (AKI)  in  43%,  infections  in  48%,  hepatic
ncephalopathy  (HE)  in  49%,  and  gastrointestinal  bleeding
n  17%.  Overall  intrahospital  mortality  and  90-day  mortal-
ty  were  36%  and  51%,  respectively.  The  main  causes  of
eath  at  90  days  were:  sepsis  (20%),  liver  failure  (24%),
nd  multiple  organ  failure  (46%).  In  that  same  study,
he  quantity  of  alcohol  consumed  was  shown  to  have
 negative  impact  on  patient  survival.  Seventy-six  per-
ent  of  the  patients  with  an  alcohol  intake  >  120  g/day
ied,  compared  with  46%  of  the  patients  that  consumed
ower  quantities  of  alcohol  (p  <  0.0001).  The  mortality
ate  in  Mexican  patients  classified  as  age-bilirubin-INR-
reatinine  (ABIC)  B  and  C  was  as  high  as  50%  and  81%,
espectively.48
Another  poor  outcome  factor  related  to  higher  mor-
ality  in  Mexican  patients  is  malnutrition.  A  study  that
ncluded  76  patients  with  AH,  of  which  76.3%  had  under-
ying  cirrhosis,  and  whose  nutritional  status  was  evaluated
hrough  the  subjective  global  assessment  (SGA),  reported
hat  38  (50%)  of  the  patients  presented  with  severe  mal-
utrition,  22  (28.9%)  were  at  risk  for  malnutrition,  and
nly  16  (21.1%)  were  well-nourished.  Overall  30-day  mor-
ality  was  60.5%  and  the  multivariate  analysis  through
ogistic  regression  showed  that  the  presence  of  severe  mal-
utrition  was  associated  with  early  death  (30  days):  odds
atio  (OR)  = 6.4;  95%  confidence  interval  (95%  CI)  =  1.9-22.1; =  0.003.49
 Alcoholic  hepatitis  is  classified  as:  a)  ‘‘definitive’’  when
there  is  histologic  confirmation;  b)  ‘‘probable’’  when  the pJ.A.  Velarde-Ruiz  Velasco  et  al.
clinical  diagnosis  is  based  on  hazardous  drinking,  active
drinking  of  up  to  eight  previous  weeks,  the  development
of  jaundice,  an  AST/ALT  ratio  >  1.5,  elevation  of  amino-
transferase  levels  usually  <  400  IU/L,  and  the  absence  of
other  causes  of  liver  injury;  and  c)  ‘‘possible’’  when  the
clinical  diagnosis  is  uncertain.
Agreement  reached:  95%  in  complete  agreement;  5%  in
artial  agreement.
AH  is  classified  as  ‘‘probable’’  when  the  following  diag-
ostic  criteria  are  clinically  met:  serum  total  bilirubin  (TB)  >
 mg/dL,  elevation  of  aspartate  aminotransferase  (AST)  and
lanine  aminotransferase  (ALT)  >  50  IU/L  but  <  400  IU/L,
nd  an  AST/ALT  ratio  >  1.5.  They  should  all  be  present  in
oth  the  clinical  and  hazardous  drinking  history  contexts
escribed  above.42,50 In  addition,  there  should  be  no  con-
ounding  factors,  i.e.,  the  autoimmune  profile  should  be
egative  (antinuclear  antibodies  [ANAs]  <  1:160  or  anti-
mooth  muscle  antibodies  [ASMAs]  <  1:80),  and  there  should
e  no  metabolic  liver  diseases,  sepsis,  shock,  cocaine  use,  or
se  of  drugs  or  herbal  medicine  with  hepatotoxic  potential
ithin  the  last  30  days.42
AH  is  considered  ‘‘definitive’’  when  the  clinical  diagnosis
as  been  confirmed  by  typical  biopsy  findings:  macrovesic-
lar  steatosis,  lobe  inflammation  with  mononuclear  cell
nfiltration  and  a predominance  of  neutrophils,  satellito-
is,  hepatocellular  lesion  identified  by  the  presence  of
allory-Denk  bodies  or  ballooning  degeneration  of  hepa-
ocytes,  necrosis,  canalicular  or  ductular  bilirubinostasis,
nd  fibrosis  that  is  typically  described  as  pericellular  and
erisinusoidal.51 Characteristic  changes  of  liver  injury  due
o  alcohol  are  venous  fibro-obliterative  lesions  and  hya-
ine  sclerosis,  which  are  not  observed  in  nonalcoholic  liver
njury.32
AH  is  classified  as  ‘‘possible’’  when  it  is  clinically  sus-
ected  but  there  are  also  confounding  factors,  such  as  the
ossibility  of  ischemic  hepatitis  in  the  face  of  severe  gas-
rointestinal  bleeding,  hypotension,  or  recent  cocaine  use;
he  possibility  of  idiosyncratic  damage  from  drugs  or  herbal
edicine;  uncertainty,  with  respect  to  alcohol  use  disorder
e.g.,  when  the  patient  denies  alcohol  use);  atypical  lab-
ratory  test  findings  (e.g.,  AST  <  50  IU/L  or  >  400  IU/L,  an
ST/ALT  ratio  < 1.5),  ANAs  >  1:160  or  ASMAs  >  1:80).  In  those
ases,  liver  biopsy  is  recommended  to  confirm  or  diagnose
H.42
 DIAGNOSTIC  TESTS  FOR  THE  DETECTION  OF  ALCOHOL-
RELATED  LIVER  DISEASE
 Liver  biopsy  can  be  performed  to  make  the  definitive
diagnosis  of  alcohol-related  liver  disease,  to  evaluate  the
exact  stage  and  hepatopathy  prognosis,  and  to  rule  out
additional  or  alternative  causes  of  liver  injury.  However,
because  it  is  an  invasive  procedure,  it  is  not  recommended
in  all  cases  and  its  risk-benefit  must  be  individually
assessed.Quality  of  evidence:  C1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  95%  in  complete  agreement;  5%  in
artial  agreement.
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Routine  liver  biopsy  is  not  recommended  for  diagnos-
ing  ALD.52--54 Steatosis  due  to  alcohol  is  apparent  through
noninvasive  imaging  studies,  such  as  ultrasound,  tomog-
raphy,  and  magnetic  resonance.  Ultrasound  is  the  most
cost-effective54 and  magnetic  resonance  is  the  most  accu-
rate  for  detecting,  and  even  quantifying,  steatosis  but
is  expensive  and  not  widely  available.55 Biochemically,
elevated  AST  and  gamma-glutamyl  transferase  (GGT)  are
indicators  of  excessive  alcohol  consumption  and  their  test-
ing  is  widely  available  in  clinical  practice.  On  the  other
hand,  liver  biopsy  is  not  considered  necessary  for  diag-
nosing  alcohol-induced  cirrhosis,  given  that  a  history  of
hazardous  drinking,  biochemical  alterations  with  elevated
AST  and  GGT  levels,  an  AST/ALT  ratio  >  1.5-2  .0,  and  ele-
vated  mean  corpuscular  volume  (MCV),  generally  in  the
context  of  macrocytic,  hyperchromic,  or  megaloblastic  ane-
mia,  as  well  as  ruling  out  chronic  viral  diseases,  such  as
hepatitis  B  or  C  and  autoimmune  diseases,  are  usually
sufficient  for  arriving  at  the  diagnosis  of  cirrhosis  due  to
ALD.52,53
In  the  context  of  ‘‘probable’’  AH,  the  clinical  criteria
are  considered  sufficient  for  making  the  diagnosis  in  clin-
ical  practice,  generally  reserving  transjugular  liver  biopsy
for  patients  with  ‘‘possible’’  AH,  as  described  above.42,56
Biopsy  findings  in  ALD  are  practically  indistinguishable
from  findings  in  nonalcoholic  fatty  liver  disease  (NAFLD),  and
therefore,  histopathologic  study  for  differentiating  between
the  two  diseases  is  not  recommended.13,57
9  Liver  stiffness  measurement  by  elastography  can  be  use-
ful  for  evaluating  liver  fibrosis  in  alcohol-related  liver
disease.
Quality  of  evidence:  B1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  95%  in  complete  agreement;  5%  in
partial  agreement.
However,  it  should  not  be  used  in  patients  with  alcoholic
hepatitis  because  it  overestimates  fibrosis  grade.
Quality  of  evidence:  C1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  85%  in  complete  agreement;  10%  in
partial  agreement.
Noninvasive  methods  for  evaluating  liver  fibrosis  are
less  validated  in  ALD,  compared  with  other  etiologies
(e.g.,  chronic  viral  hepatitis  or  nonalcoholic  steatohepatitis
[NASH]).32
Among  the  radiologic  techniques  available  for  evaluat-
ing  fibrosis,  elastography  is  well  validated  for  detecting
advanced  fibrosis  and  performs  better  in  ruling  out  the  pres-
ence  of  cirrhosis  than  confirming  it.58 There  is  no  agreement
as  to  the  cutoff  values  for  defining  cirrhosis  in  the  context
of  ALD  and  there  is  a  risk  for  false  positives  in  patients  with
active  alcohol  consumption.32 In  a  recent  systematic  review
with  a  meta-analysis,  the  diagnostic  accuracy  of  transitory
elastography  for  establishing  fibrosis  grade  in  patients  with
ALD  was  evaluated.  Those  authors  suggested  utilizing  a  cut-
off  value  <  9.5  kPa  to  rule  out  advanced  fibrosis  (F3)  and
a  cutoff  value  <  12.5  kPa  to  rule  out  cirrhosis  (F4).  How-
ever,  they  also  recommended  caution  with  respect  to  their
results,  given  that  the  majority  of  data  from  the  review
came  from  retrospective  studies  and  the  overall  risk  for
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ias  was  high  for  most  of  the  studies  analyzed.  In  addition,
rospective  studies  are  required  that  evaluate  the  accuracy
f  the  cutoff  values  proposed.59
Elastography  is  not  recommended  for  estimating  liver
brosis  grade  in  patients  with  AH  because  the  presence
f  hepatic  inflammation,  as  well  as  systemic  inflamma-
ion,  cholestasis,  hyperbilirubinemia,  steatosis,  and  hepatic
ein  congestion,  among  others,  overestimate  the  grade  of
brosis.60
0  Ultrasound,  tomography,  and  magnetic  resonance  can
quantify  steatosis  and  help  rule  out  other  causes  of
chronic  liver  injury  and  can  also  recognize  advanced
disease  (cirrhosis)  and  its  complications.  However,  they
cannot  distinguish  whether  injury  is  secondary  to  alcohol
or  to  other  etiologies.
Quality  of  evidence:  C1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  95%  in  complete  agreement;  5%  in
artial  agreement.
Ultrasound,  tomography,  and  magnetic  resonance  are
seful  for  detecting  steatosis,61 but  ultrasound  is  the  imag-
ng  method  with  lower  sensitivity  and  specificity,  especially
hen  the  steatosis  affects  at  least  20-30%  of  the  liver
arenchyma.  The  controlled  attenuation  parameter  (CAP)
as  been  shown  to  be  useful  in  quantifying  hepatic  steato-
is  but  it  is  not  specific  for  ALD  and  therefore  does  not
istinguish  alcoholic  steatosis  from  steatosis  secondary  to
ny  other  etiology.  When  a  patient  suffers  from  other  dis-
ases  (e.g.,  hepatitis  B  or  C,  metabolic  syndrome,  obesity,
tc.),  in  addition  to  hazardous  drinking,  the  result  should
e  interpreted  according  to  the  appropriate  clinical  context
nd  in  an  individualized  manner.62,63 Magnetic  resonance  can
etect  steatosis  if  5-10%  of  the  parenchyma  is  affected.
agnetic  resonance  elastography  is  more  expensive,  and
enerally  less  available,  but  it  is  more  accurate  for  estimat-
ng  steatosis  and  fibrosis  grades,  compared  with  other  types
f  elastography.64
Imaging  studies  do  not  distinguish  between  ALD  and  other
tiologies  as  causes  of  hepatopathy,  but  they  are  useful
or  anatomically  evaluating  the  liver  and  bile  ducts  and  for
uling  out  primary  and  secondary  obstructive  processes.  In
he  context  of  the  cirrhotic  patient,  regardless  of  etiology,
hey  are  useful  for  evaluating  the  presence  and  magnitude
f  complications  derived  from  portal  hypertension:  ascites,
ollateral  vessels,  and  focal  lesions.61
1  In  patients  suspected  of  presenting  with  alcoholic  hep-
atitis  and  jaundice,  ultrasound  is  recommended  as  a
screening  tool  for  differentiating  obstructive  processes
of  the  bile  ducts.
Quality  of  evidence:  C1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
Ultrasound  is  the  first-line  noninvasive  imaging  techniquehat  enables  intrahepatic  cholestasis  to  be  differentiated
rom  extrahepatic  cholestasis.  Ultrasound  is  extremely
ccurate  for  identifying  the  site  and  cause  of  a  biliary
bstructive  process.65 It  is  also  cost-effective  for  identifying
3a
t
1
e
A
t
f
t
O
r
a
b
C
t
A
(
e
N
s
s
b
s
G
1
o
u
d
d
o
t
d
g
a
A
e
m
o
b
H
r
d
fi
1
h
t
o
c
t
d
T
r
b
a
r
t
T
f
i
o
m
s
d
i
s
o
a
q
w
1
f
o
>
i
t40  
n  obstructive  process  and  distinguishing  it  from  nonobstruc-
ive  jaundice.66
2  When  there  is  doubt,  or  a  history  of  hazardous  drinking
cannot  be  readily  established  in  the  patient,  an  alco-
holic  liver  disease/nonalcoholic  fatty  liver  disease  index
(ANI)  above  0  indicates  the  likelihood  of  alcoholic  liver
disease.
Quality  of  evidence:  B1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
The  alcoholic  liver  disease/nonalcoholic  fatty  liver  dis-
ase  index  (ANI)  is  a  highly  accurate  tool  for  differentiating
LD  from  NAFLD.  Its  application  is  recommendable  when
here  is  doubt  with  respect  to  hazardous  drinking  as  a trigger
or  liver  injury  in  the  presence  of  steatohepatitis.  Short-
erm  alcoholic  abstinence  does  not  affect  the  ANI  result.
ther  liver  diseases  (e.g.,  viral  or  autoimmune)  should  be
uled  out  before  applying  the  ANI.  That  index  is  more
ccurate  when  the  MELD  score  is  under  20.  The  ANI  can
e  calculated  free  of  charge  on  the  website  of  the  Mayo
linic.67
The  most  relevant  variables  identified  through  the  logis-
ic  regression  analysis  that  are  able  to  distinguish  between
LD  and  NAFLD  are:  MCV,  the  AST/ALT  ratio,  body  mass  index
BMI),  and  sex.  An  ANI  value  above  zero  favors  alcohol  as  the
tiology  and  an  ANI  value  below  zero  favors  the  diagnosis  of
AFLD.  The  ANI  had  a  c-statistic  of  0.989  in  the  derivation
ample  and  0.974,  0.989,  and  0.767  in  the  three  validation
amples  of  the  model.  The  ANI  is  superior  for  differences
etween  ALD  and  NAFLD,  compared  with  other  biomarkers,
uch  as  protein  tyrosine  phosphatase  1b,  the  AST/ALT  ratio,
GT,  and  carbohydrate-deficient  transferrin.68
C  DIAGNOSIS  OF  ALCOHOLIC  HEPATITIS
3  Alcoholic  hepatitis  is  a  clinical  entity  characterized  by
the  sudden  onset  of  jaundice  and  aminotransferase  ele-
vation  (particularly  AST)  that  occur  in  patients  with
continuous  drinking  in  the  hazardous  drinking  range.
When  severe,  other  signs  of  liver  decompensation  can
also  be  found,  such  as  bacterial  infection,  ascites,
variceal  bleeding  and/or  encephalopathy.
Quality  of  evidence:  C1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
Severe  AH  is  a  clinical  entity  characterized  by  the  sudden
nset  of  jaundice  and  elevated  aminotransferases,  partic-
larly  AST,  that  occur  after  having  engaged  in  hazardous
rinking  for  more  than  six  months,  with  fewer  than  60
ays  (eight  weeks)  of  abstinence  before  the  presentation
f  jaundice.50 The  cutoff  point  with  respect  to  the  dura-
ion  of  drinking  and  quantity  of  alcohol  related  to  the
evelopment  of  AH  are  not  completely  established,  but  in
eneral,  an  average  alcohol  intake  ≥  40  g/day  for  women
nd  ≥  50-60  g/day  for  men  is  a  reasonable  parameter  for
H  diagnosis.  Regarding  duration,  patients  with  AH  gen-
rally  have  a  history  of  intense  alcohol  consumption  for
ore  than  five  years,  possibly  having  had  intermittent  peri-
ds  of  abstinence.42 Jaundice  is  frequently  accompanied
y  fatigue,  hepatomegaly,  and  decompensation  (ascites,
1J.A.  Velarde-Ruiz  Velasco  et  al.
E,  bacterial  infection,  variceal  bleeding).  Liver  biopsy
eveals  steatohepatitis  with  Mallory-Denk  bodies,  ballooning
egeneration  of  hepatocytes,  bilirubinostasis,  and  advanced
brosis/cirrhosis. 43
4  A  detailed  clinical  history  can  identify  alcohol  as  a  liver
aggressor.  It  can  be  supported  by  the  AUDIT,  AUDIT-C,
and  CAGE  scales.
Quality  of  evidence:  B1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
Different  questionnaires  are  available  for  detecting  alco-
ol  use  disorder  and  have  generally  shown  greater  sensitivity
han  any  of  the  biochemical  tests  at  hand.69,70
The  CAGE  (acronym  for  cut  down,  annoyed,  guilty,  eye-
pener)  is  among  the  more  widely  used  questionnaires  and
onsists  of  four  simple  questions.  If  the  answer  is  ‘‘yes’’
o  two  or  more  of  the  questions,  severe  alcohol  depen-
ence  (the  term  used  in  the  DSM-IV)  is  positively  correlated.
he  CAGE  questionnaire  has  been  widely  validated,  with  a
eported  sensitivity  between  91%  and  95%  and  specificity
etween  76%  and  77%  for  identifying  patients  with  excessive
lcohol  consumption  and  alcohol  dependency  or  alcoholism,
espectively  (DSM-IV).  However,  it  has  a  much  lower  sensi-
ivity  than  that  of  the  Alcohol  Use  Disorders  Identification
est  (AUDIT):  40%  vs.  93%,  respectively.71
The  AUDIT  questionnaire  is  considered  the  gold  standard
or  identifying  hazardous  drinking.71 Designed  by  the  WHO,
t  has  been  widely  validated  for  detecting  alcohol  use  dis-
rder,  even  when  mild.  Its  simple  format  is  made  up  of  10
ultiple  choice  questions  whose  answers  are  marked  on  a
cale  from  0  to  4.  A  result  ≥  8  indicates  alcohol  use  disor-
er  (92%  sensitivity  and  94%  specificity)  and  a  result  ≥  20
ndicates  severe  alcohol  use  disorder.72
The  AUDIT-C  is  a  simplified  version  of  the  AUDIT.  It  has  a
imilar  sensitivity  and  specificity  to  the  AUDIT  and  consists
f  4  multiple  choice  questions.  Practical  online  calculators
re  also  available.  As  with  the  AUDIT,  and  the  answer  to  each
uestion  is  marked  on  a  scale  from  0  to  4.  A  score  ≥  3  for
omen  and  ≥  4  for  men  indicates  alcohol  use  disorder.73
5  There  is  no  specific  biomarker  for  the  diagnosis  of
alcoholic  hepatitis.  Alterations  that  aid  in  diagnosing
alcoholic  hepatitis  are  leukocytosis  with  neutrophilia,
hyperbilirubinemia  (generally  >  3  mg/dL),  AST  >  50  U/L
(usually  <  400  U/L),  and  an  AST/ALT  ratio  >  1.5-2  .0.
Quality  of  evidence:  C1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
To  make  the  clinical  diagnosis  of  AH  (‘‘possible’’  AH),  the
ollowing  values  are  indispensable:  TB  >  3 mg/dL,  elevation
f  AST  and  ALT  >  50  IU/L  but  <  400  IU/L,  and  an  AST/ALT  ratio
 1.5  (previously,  it  was  an  AST/ALT  >  2).42,50,56 AH  diagnosis
s  supported  by  neutrophilic  leukocytosis,  coagulopathy,  and
hrombocytopenia.436  Liver  biopsy  is  utilized  to  confirm  diagnosis,  but  it  is  not
indispensable  and  should  be  reserved  for  cases  in  which
there  is  diagnostic  uncertainty.
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1The  Mexican  consensus  on  alcoholic  hepatitis  
Quality  of  evidence:  C1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
In  clinical  practice,  percutaneous  ultrasound-guided  liver
biopsy  or  transjugular  liver  biopsy  can  be  performed  due  to
the  frequent  presence  of  thrombocytopenia  and  coagulopa-
thy  in  patients  with  AH.  The  transjugular  approach  appears
to  be  the  route  of  choice.54--56 Nevertheless,  in  patients  with
‘‘probable’’  AH,  liver  biopsy  is  not  essential,  given  that
the  possibility  of  finding  a  diagnosis  different  from  AH  in
the  histopathologic  study  is  less  than  10%.  On  the  other
hand,  liver  biopsy  is  indeed  recommended  in  patients  with
‘‘possible’’  AH  to  either  confirm  or  rule  out  the  diagnosis  of
AH.42
17  Histopathologic  findings,  such  as  macrovesicular  steato-
sis,  steatohepatitis,  ballooning  degeneration  of  hepato-
cytes,  infiltration  of  polymorphonuclear  neutrophils,  and
Mallory-Denk  bodies,  can  aid  in  making  the  diagnosis,  but
they  are  not  pathognomonic.
Quality  of  evidence:  B1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
The  definitive  diagnosis  of  AH  is  made  through  liver
biopsy.42,48,49 It  is  also  useful  for  estimating  the  short-term
outcome  of  AH50 and  alcohol-related  acute-on-chronic  liver
failure.51 Fibrosis  grade  (bridging,  advanced,  or  the  pres-
ence  of  cirrhosis),  a  severe  grade  of  neutrophilic  infiltration,
and  the  type  of  hepatocellular  bilirubinostasis,  added  to  the
presence  of  ductular  or  canalicular  bilirubinostasis  and  the
presence  of  megamitochondria,  are  histologic  factors  inde-
pendently  associated  with  90-day  mortality.  In  addition,  the
type  of  bilirubinostasis  with  hepatocellular  plus  ductular  or
canalicular  involvement,  is  also  a  predictive  factor  for  the
development  of  bacterial  infections.52 Those  findings  are  not
pathognomonic.  NASH  can  histologically  present  with  simi-
lar  findings,  thus  the  clinical  criterion  is  fundamental  for
diagnosing  AH.51,57
D.  EVALUATION  AND  PROGNOSIS  OF  PATIENTS  WITH  ALCO-
HOLIC  HEPATITIS
18  Complete  nutritional,  psychologic,  psychiatric,  and
social  work  evaluations  should  be  carried  out  in  all
patients  with  alcoholic  hepatitis.
Quality  of  evidence:  A1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
For  several  years,  patients  with  AH  and  malnutrition
have  been  reported  to  have  higher  rates  of  morbidity
and  mortality.74 That  has  been  corroborated  in  the  Mex-
ican  population,  with  the  report  that  malnutrition,  as  an
independent  risk  factor,  increases  mortality  in  Mexican  AH
patients.  Higuera-de  la  Tijera  et  al.  found  that  severe  mal-
nutrition  was  associated  with  a  higher  30-day  mortality  rate
(OR  =  6.4;  95%  CI  =  1.9-22.1;  p  =  0.003).49
The  European  Society  for  Clinical  Nutrition  and
Metabolism  (ESPEN)  recommends  offering  nutritional  ther-
apy  to  all  patients  with  severe  AH  that  do  not  meet
the  caloric  requirements  for  spontaneous  dietary  intake
to  improve  survival,  reduce  infection  rates,  improve  liver341
unction,  and  resolve  HE,  if  present.  However,  survival
mprovement  has  not  been  demonstrated  in  different  meta-
nalyses.75
A  daily  caloric  intake  of  35-40  kcal/kg  and  a daily  pro-
ein  intake  of  1.2-1.5  g/kg  are  recommended.  Nevertheless,
hey  are  difficult-to-achieve  objectives  in  clinical  practice.
herefore,  patients  that  do  not  meet  those  requirements
hould  be  given  enteral  nutritional  support  through  a
asoenteral  tube.75
In  the  most  recent  multicenter  study  that  combined
teroids  and  enteral  diet,  no  improvement  in  survival  was
emonstrated  with  their  combination  but  there  was  a  sig-
ificantly  higher  mortality  rate  in  the  patients  that  had  a
ypocaloric  diet  (21.5  Kcal  x  kg-1 x  d-1).76
Likewise,  micronutrient  supplementation,  such  as  the  B
omplex  (especially  thiamine),  vitamin  D,  and  zinc,  is  rec-
mmended  by  the  ESPEN.74
For  the  abovementioned  reasons,  the  present  consensus
ecommends  that  all  patients  with  AH  have  an  ade-
uate  nutritional  evaluation,  a  daily  energy  intake  of
5-40  kcal/kg,  a  daily  protein  intake  of  1.2-1.5  g/kg,  and
hat  they  receive  micronutrient  supplementation.
The  oral  route  should  be  the  first  feeding  option  but
asoenteral  administration  can  be  used  if  there  is  an  impedi-
ent,  such  as  HE,  cough  syncope,  or  swallowing  alterations.
arenteral  feeding  should  be  used  as  a  last  resort  and  only
n  patients  contraindicated  for  enteral  feeding.
Patients  with  alcohol  use  disorder  have  a  high  prevalence
f  psychiatric  comorbidity,  especially  anxiety  disorders,
ood  disorders,  psychosis,  post-traumatic  stress  disorder,
nd  schizophrenia.77 They  can  also  have  a  history  of  sexual
buse,  physical  abuse,  and  social  isolation.50 Such  factors
an  increase  the  risk  for  alcohol  relapse.  Therefore,  the
resent  consensus  recommends  evaluations  by  psychologists
nd  psychiatrists  that  should  be  in  charge  of  substance  abuse
anagement,  including  alcohol.
There  is  also  a  high  risk  for  developing  other  addictions
o  substances  such  as  opioids,  benzodiazepines,  and  nico-
ine.  The  synergy  of  smoking  and  drinking  is  an  important
isk  factor  for  cardiovascular  diseases  and  cancer,  includ-
ng  hepatocellular  carcinoma.  Due  to  the  fact  that  patients
ith  alcohol  use  disorder  are  heavy  smokers,  psychologic
nd  psychiatric  evaluation  and  referral  to  addiction  clinics
re  recommended.28,78
In  addition,  evaluation  by  a  social  work  team  is  recom-
ended  because  any  addiction,  including  that  of  alcohol,
dversely  affects  the  family  system  and  all  its  members,
ncluding  children,  thus  contributing  to  family  separation.
he  financial  and  emotional  burden  caused  by  the  disease
esults  in  the  suffering  of  the  individual  family  members.
hildren  that  have  a  parent  with  an  addition  are  at  an
ncreased  risk  for  low  academic  performance,  behavior  dis-
rders,  psychiatric  disorders,  and  presenting  with  substance
buse,  themselves.79
9  The  comprehensive  evaluation  of  the  patient  with  con-
firmed  alcoholic  hepatitis  should  include:
a)  the  search  for  infectious  foci.
b)  the  ruling  out  of  gastrointestinal  bleeding.
c)  the  ruling  out  of  encephalopathy.
d)  the  ruling  out  of  acute  kidney  injury.
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242  
e)  the  search  for  chronic  complications  of  hepatopathy
Quality  of  evidence:  A1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
It  is  vitally  important  to  search  for  primary  infection
ites  because  they  can  be  poor  outcome  factors.  Undetected
nd  untreated  infections  can  lead  to  the  development  of
cute  kidney  injury  (AKI)  and  multiple  organ  failure,  increas-
ng  mortality.  Louvet  et  al.  reported  a  25%  infection  rate
n  patients  with  severe  AH  upon  hospital  admission  and
he  mortality  rate  at  two  months  increased  by  30%  in  the
nfected  patients.80 In  the  STOPAH  study,  24%  of  the  deaths
ere  in  patients  with  infections.81
A  high  level  of  suspicion  is  needed  to  identify  bacterial
r  fungal  infections,  given  that  cardinal  signs,  such  as  fever,
an  be  absent.  Other  signs,  such  as  tachycardia  and  leukocy-
osis  may  not  be  very  specific  for  infection  in  those  patients.
ystemic  inflammatory  response  syndrome  (SIRS)  can  be
resent,  with  or  without  infection  upon  hospital  admission,
nd  is  a  risk  factor  for  the  development  of  multiple  organ
ailure.  Serum  procalcitonin  is  a  useful  marker  for  detecting
acterial  infections.82 Similar  to  the  European  guidelines,
e  recommend  herein  the  performance  of  chest  x-ray,  uri-
alysis,  diagnostic  paracentesis  in  the  patient  with  ascites,
nd  the  ruling  out  of  soft  tissue  infections.  Pan-culturing  is
lso  strongly  recommended  in  all  patients.28
Another  recommendation  is  ruling  out  the  presence  of
KI,  given  that  it  has  been  reported  as  one  of  the  most
mportant  predictors  of  90-day  mortality.  The  presence  of
IRS,  increased  bilirubin  level,  and  coagulopathy  upon  hos-
ital  admission  are  useful  predictors  for  the  development  of
KI.83
In  an  observational  study  of  71  Mexican  patients,  Higuera-
e  la  Tijera  et  al.  found  that  the  quantity  of  alcohol
onsumed  was  related  to  AKI,  reporting  intakes  of  219  g/day
s.  101  g/day;  p  =  0.001.  They  also  found  that  the  pres-
nce  of  AKI  was  an  isolated  associated  factor  for  greater
isk  of  death  (RR  =  6.7,  p  =  0.02).  Strikingly,  the  presence
f  other  complications  that  should  be  monitored,  such  as
pper  gastrointestinal  bleeding  (UGIB)  or  HE,  did  not,  sep-
rately,  increase  mortality,  but  their  combination  or  the
dded  presence  of  AKI,  resulted  in  an  increase  in  mor-
ality.  The  following  combinations  behaved  as  predictive
actors  of  death:  AKI  plus  HE  (RR  =  8.9,  p  =  0.001)  and  HE  plus
GIB  (RR  =  6.7,  p  =  0.01).  The  presence  of  AKI,  UGIB,  and  HE
howed  the  highest  risk  (RR  =  10.0,  p  =  0.001).84
0  The  severity  of  alcoholic  hepatitis  should  be  established,
as  it  defines  the  type  of  treatment  to  administer.
Quality  of  evidence:  A1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
1  The  application  of  the  different  scales  (MDF,  MELD,  Glas-
gow,  ABIC)  is  useful  for  establishing  disease  severity,
predicting  mortality,  and  indicating  corticosteroid  treat-
ment.
Quality  of  evidence:  B1.
Strength  of  recommendation:  strong,  in  favor  of.
t
nJ.A.  Velarde-Ruiz  Velasco  et  al.
Agreement  reached:  100%  in  complete  agreement.
Determining  the  severity  of  disease  in  patients  with  AH  is
ssential  because  it  establishes  the  conduct  to  be  followed,
uch  as  whether  the  patient  should  be  hospitalized  or  man-
ged  as  an  outpatient,  the  treatment  to  be  employed,  and
he  prognosis  for  survival.
There  are  different  scales  for  determining  disease  sever-
ty.  MDF  was  the  first  scale  that  differentiated  individuals
ith  higher  short-term  mortality,  and  it  continues  to  be  one
f  the  most  widely  used.85 A  cutoff  point  ≥  32  identifies
atients  with  severe  AH  and  high  short-term  mortality  (  20-
0%  ).  Thirty-day  mortality  is  under  10%  in  patients  with  mild
H  (MDF  <  32).28,50,81,85--87
Other  severity  evaluation  scales  include:
 MELD
 ABIC
 Glasgow
The  MELD  is  already  a well-validated  prognostic  score  for
dvanced  liver  disease.  It  has  also  been  shown  to  be  useful
or  evaluating  mortality  in  AH,  in  which  a  MELD  score  ≥  20
uggests  elevated  30-day  and  90-day  mortality.28,50,86
The  acronym  ABIC  signifies  A  for  age,  B  for  serum  biliru-
in,  I  for  INR,  and  C  for  serum  creatinine.  The  calculated
0-day  mortality  risk  on  the  ABIC  scale  is  6.71  (low  risk),
.71-9  (intermediate  risk),  and  ≥  9  (high  risk),  with  reported
urvival  of  100%,  70%,  and  25%,  respectively.28,50,86,87
The  Glasgow  scale  is  more  recent  and  utilizes  the  fol-
owing  variables:  age,  serum  bilirubin  from  day  one,  urea
rom  day  one,  bilirubin  from  days  6-9,  prothrombin  time,
nd  peripheral  leukocyte  count.  The  score  ranges  from  5-
2,  the  cutoff  point  for  defining  severity  is  ≥  9,  and  90-day
ortality  is  52%.28,50,87
Forrest  et  al.  recently  conducted  a study  on  patients  from
he  STOPAH  trial,  in  which  they  compared  the  effectiveness
f  the  different  scales  (MDF,  MELD,  ABIC,  Glasgow)  for  pre-
icting  mortality  at  28  days  and  at  90  days.  They  reported
hat  the  MDF  had  poorer  performance  and  concluded  that
he  MELD,  ABIC,  and  Glasgow  scales  were  superior  for  pre-
icting  mortality  (AUROC:  0.670,  0.704,  0.726,  and  0.713,
espectively).88
In  Mexico,  Altamirano  et  al.  reported  that  the  ABIC  and
ELD  scales  had  better  performance  and  prognostic  accu-
acy  for  predicting  severity  and  mortality  in  a  Mexican
opulation,  with  an  AUROC  of  82  and  83,  respectively.48
The  present  consensus  recommends  establishing  the
everity  and  prognosis  of  AH  by  utilizing  any  of  the  scales
escribed  above  to  define  the  starting  of  steroid  manage-
ent.
2  The  Lille  model  is  useful  for  evaluating  treatment
response  and  is  calculated  seven  days  after  starting
corticosteroid  treatment.  If  it  is  >  0.45,  the  patient  is
considered  a  nonresponder.
Quality  of  evidence:  B1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
The  scarceness  of  effective  therapies  for  severe  AH  and
he  need  for  early  identification  of  the  patients  that  do
ot  respond  to  steroids  led  to  the  development  of  the  Lille
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oThe  Mexican  consensus  on  alcoholic  hepatitis  
model.89 It  includes  six  variables:  age,  creatinine,  albu-
min,  prothrombin  time,  TB,  and  TB  evolution  at  day  seven.
Patients  with  a  Lille  model  score  ≥  0.45  have  a  six-month
survival  rate  of  25%,  compared  with  an  85%  rate  in  oth-
ers,  suggesting  they  are  nonresponders  and  should  suspend
steroid  treatment.  The  main  advantage  of  the  Lille  model
is  its  dynamic  component  in  relation  to  TB  evolution,  which
is  the  most  accurate  and  precise  variable  for  predicting  six-
month  mortality.87
In  a  meta-analysis  by  Mathurin  et  al.  that  newly  evalu-
ated  the  Lille  model,  they  identified  three  patient  groups
according  to  steroid  response:  1)  complete  responders  (Lille
model  score  ≤  0.16),  2)  partial  responders  (Lille  model  score
of  0.16-0.56),  and  3)  nonresponders  (Lille  model  score  ≥
0.56),  providing  a  window  for  suspending  steroids  in  the
nonresponders.90
Applying  the  Lille  model  on  day  four  of  steroid  treatment
was  recently  shown  to  be  similar  to  applying  it  on  day  seven,
in  relation  to  accuracy  for  predicting  mortality,  but  that
finding  needs  to  be  validated.91 On  the  other  hand,  Louvet
et  al.  demonstrated  the  usefulness  of  combining  the  differ-
ent  scales  and  reported  that  the  best  combination  was  that
of  the  Lille  model  +  the  MELD  score  for  predicting  mortality
in  severe  AH  patients  more  accurately.92
23  Alcohol  abstinence  is  the  most  important  prognostic
factor  for  long-term  survival  in  patients  with  alcoholic
hepatitis.  In  the  short  term,  mortality  is  determined
by  causes  related  to  inflammatory  response,  liver  injury
(variceal  bleeding,  portal  hypertension),  infections,  and
organ  failure.
Quality  of  evidence:  B1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
Long-term  survival  after  a  severe  episode  of  AH  is  strongly
related  to  successful  alcohol  abstinence.  Louvet  et  al.
conducted  a  study  that  described  factors  for  predicting
short-term  and  long-term  survival,  reporting  that  alcohol
intake,  defined  as  ≥  30  g/day,  was  not  associated  with  short-
term  mortality  (p  =  0.24)  but  was  strongly  associated  with
long-term  mortality  (>  6  months),  with  a  hazard  ratio  (HR)  of
3.9  (p  <  0.001).  They  also  reported  the  association  between
the  quantity  of  alcohol  consumed  and  long-term  mortal-
ity:  HR  =  2.36  (p  =  0.052)  for  intake  of  1-29  g/day;  HR  =  3.2
(p  =  0.003)  for  intake  of  30-49  g/day;  HR  =  3.51  (p  =  0.0001)
for  intake  of  50-99  g/day;  and  HR  =  5.61  (p  =  0.0001)  for
intake  >  100  g/day,93,94 implying  that  the  cornerstone  of  sur-
vival  improvement  is  the  effective  management  of  alcohol
use  disorder.28
Short-term  survival  is  determined  by  the  presence  of
SIRS,  regardless  of  the  presence  of  infection,  and  decreases
if  it  presents  together  with  variceal  bleeding,  AKI,  or  HE.28,82
Higuera-de  la  Tijera  et  al.  have  demonstrated  an  increase
in  short-term  mortality  in  Mexican  patients  with  severe
AH  +  AKI  (RR  of  6.7,  p  =  0.02).  They  also  showed  that  the
combination  of  AKI  +  UGIB  +  HE  elevated  the  risk  of  death
to  a  RR  of  10,  p  =  0.001.84
E.  TREATMENT  OF  FIBROSIS  DUE  TO  ALCOHOL-RELATED
LIVER  DISEASE
a
o
p343
4  The  time  at  which  fibrosis  becomes  irreversible  is  not
precisely  known  in  patients  with  alcoholic  hepatitis.
However,  there  is  evidence  that  eliminating  alcohol  con-
sumption  can  reverse  or  stop  fibrosis.
Quality  of  evidence:  B1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
Some  of  the  complications  observed  in  ALD  are  not  due
o  the  inherent  toxicity  of  alcohol  but  are  a  result  of  the
ifferent  stages  of  liver  fibrosis.  Despite  the  fact  that  the
revention  and  detention  of  fibrosis  is  an  adequate  aim  in
hat  context,  the  exact  time  at  which  it  begins,  the  individ-
al  phenomena  that  determine  the  pattern  of  progression,
nd  the  point  at  which  fibrosis  becomes  irreversible  are  not
nown.  The  main  factors  for  the  development  and  progres-
ion  of  ALD  are  quantity  of  alcohol  consumed,  consumption
uration,  consumption  pattern,  hepatitis  viruses,  interac-
ions  with  the  environment  of  the  host,  sex,  genetic  factors,
nd  nutritional  factors.95 For  reasons  not  yet  understood,
ost  heavy  drinkers  do  not  develop  severe  liver  disease  with
brosis.  The  majority  develop  alcoholic  fatty  liver  but  only
0-35%  develop  alcoholic  steatohepatitis  and  8-20%  develop
irrhosis  of  the  liver,  even  with  an  alcohol  intake  of  12-
4  g/day.96
At  any  rate,  sustained  alcohol  consumption  is  related
o  episodes  of  AH,  which  leads  to  more  serious  cases
f  decompensated  ALD,  and  in  turn,  greater  morbidity
nd  mortality.  It  is  the  main  risk  factor  for  liver  injury
nd  its  complications.95 In  addition,  the  coexistence  of
ustained  alcohol  consumption  with  other  hepatic  comor-
idities  (NAFLD,  chronic  hepatitis  C,  chronic  hepatitis  B,
etabolic  liver  disease,  or  autoimmune  liver,  etc.)  increases
he  risk  for  fibrosis.96,97 Therefore,  total  and  sustained
lcohol  abstinence  is  the  cornerstone  for  stopping,  and
ven  reversing,  alcohol-related  liver  fibrosis,  as  long  as  the
hreshold  of  irreversible  injury  has  not  been  crossed.28,50,98
5  There  is  no  evidence  that  any  medication  (ursodeoxy-
cholic  acid,  chenodeoxycholic  acid,  obeticholic  acid,  or
others)  is  beneficial  for  the  regression  of  fibrosis  due  to
alcohol-related  liver  disease,  especially  alcoholic  hep-
atitis.
Quality  of  evidence:  B1
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  95.5%  in  complete  agreement;  4.5%
n  complete  disagreement.
Even  though  there  is  evidence,  as  well  as  patho-
hysiologic  principles,  that  demonstrate  the  usefulness  of
rsodeoxycholic  acid,  chenodeoxycholic  acid,  and  obeti-
holic  acid  for  stopping  fibrosis  progression  in  experimental
holestatic  liver  disease  and  NAFLD  models,  at  present  there
re  no  clinical  trials  that  show  safety  and  effectiveness  in
elation  to  histologic  improvement  of  the  inflammatory  pro-
ess  or  fibrosis  regression  in  ALD  at  any  of  its  different  stages
r  degrees  of  injury,  including  AH.98--101A  phase  2  study  is  currently  being  conducted  that  is
nalyzing  the  changes  in  the  MELD  score  after  six  weeks
f  obeticholic  acid  administration,  and  the  results  are
ending.101
3 J.A.  Velarde-Ruiz  Velasco  et  al.
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Table  4  Contraindications  for  corticosteroid  use  in
patients  with  acute  alcoholic  hepatitis 28,115,116.
Absolute
[•]Active  Hepatitis  B  virus  infection
• Active  tuberculosis
Relative
[•]Active  infection  or  sepsis
• Uncontrolled  diabetes  mellitus
• Uncontrolled  gastrointestinal  bleeding
• Acute  kidney  injury  (creatinine  >  2.5  mg/dL)
• Acute  pancreatitis
• HIV  infection  or  hepatitis  C  infection
• Hepatocellular  carcinoma
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6  There  is  no  evidence  that  antioxidants  (silymarin,  vita-
min  E)  reduce  hepatic  inflammatory  damage  or  lead  to
the  regression  of  fibrosis  in  patients  with  alcoholic  hep-
atitis.
Quality  of  evidence:  C1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  95.5%  in  complete  agreement;  4.5%
n  complete  disagreement.
Despite  the  fact  that  silymarin  is  a  product  with  great
ommercial  success  that  is  popularly  perceived  as  appar-
ntly  harmless,  there  is  no  evidence  of  its  usefulness  in
H.102 According  to  two  reviews  in  the  medical  literature
a  meta-analysis  and  an  evidence  report),  there  are  no
onclusive  benefits  that  support  the  prescription  of  that
ntioxidant  and  the  studies  analyzed  were  greatly  het-
rogeneous,  with  conflicting  results.103--105 With  respect  to
itamin  supplements,  including  vitamin  E,  there  is  no  sci-
ntific  evidence  supporting  their  use  as  monotherapy  or  in
ombination  with  traditional  treatment  for  AH.106
F.  TREATMENT  OF  ALCOHOLIC  HEPATITIS
7  The  therapeutic  strategy  that  remains  a  cornerstone  of
treatment  for  acute  alcoholic  hepatitis  is  alcohol  absti-
nence.
Quality  of  evidence:  A1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
Given  that  AH,  by  definition,  requires  significant  alco-
ol  consumption  that  is  sustained  and  recent,  and  added  to
he  individual  and  environmental  risks  involved,  alcohol  sus-
ension  is  the  imperative  measure  recommended  for  those
uffering  with  the  disease.  Maintaining  abstinence  beyond  90
ays  after  the  onset  of  AH  is  especially  important  because
hat  is  the  expected  threshold  of  time  for  a  process  of  liver
unction  recovery  to  take  place.107 Patients  that  begin  to
rink  again  are  known  to  have  a  worse  outcome,  in  general.
n  the  STOPAH  study,  sustained  alcohol  abstinence  was  the
ingle  factor  associated  with  one-year  survival.  That  benefit
as  lost  with  as  little  as  one  to  two  alcoholic  beverages  per
ay,  increasing  mortality.81,108 The  present  consensus  group
rmly  believes  that  multidisciplinary  management  is  nec-
ssary  for  the  treatment  of  alcohol  use  disorder  that  must
nclude  evaluations  in  the  areas  of  social  work,  psychology,
nd  psychiatry,  as  well  as  guaranteeing  an  adequate  support
etwork.
8  Nutritional  support  is  essential  in  the  treatment  of  alco-
holic  hepatitis.  The  recommended  caloric  intake  is  35-
40  cal/kg/day,  with  protein  intake  of  1.2-1.5  g/kg/day.
It  is  also  important  to  treat  other  nutrient  deficiencies,
such  as  those  of  vitamins  and  minerals.
Quality  of  evidence:  B1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
Albeit  controversial,  nutritional  support  has  acquiredreat  importance  in  the  context  of  AH  because  it  has
een  shown  to  be  beneficial  in  relation  to  the  mortality
ate  and  the  development  of  HE  and  infections.109 A  sup-
lemented  diet  has  not  been  more  advantageous  than  an
c
t
t
t• Idiosyncratic  drug-induced  liver  injury
nsupplemented  one,  therefore,  the  priority  is  to  focus  on
he  caloric  content,  which,  when  under  21.5  kcal/kg/day,
mpacts  mortality.  Particularly  for  severe  AH,  the  current
ecommendation  is  a  protein  intake  of  1.2-1.5  g/kg,  with
 caloric  intake  of  35-40  kcal/kg.28,50 Enteral  nutrition  as
onotherapy  has  even  been  compared  with  prednisolone,
escribing  statistical  similarities  in  the  clinical  outcomes.110
valuation  by  nutrition  personnel  should  be  implemented  at
he  time  of  diagnosis  because  the  effects  of  malnutrition
nd  catabolism  can  influence  the  response  to  pharmacologic
reatment  with  steroids,  increase  the  risk  for  infection,  and
ncrease  morbidity  and  mortality.111
9  Treatment  with  corticosteroids  in  alcoholic  hepatitis  is
indicated  in  cases  of  severe  acute  alcoholic  hepatitis
(MDF  score  above  32  or  MELD  score  above  20).
Quality  of  evidence:  A1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
Pharmacologic  treatment  with  corticosteroids  in  AH  is
ustified  only  in  severe  cases  defined  by  an  MDF  score  ≥
2  or  a  MELD  score  >  20,  as  long  as  there  are  no  con-
raindications  for  their  administration.  The  drug  of  choice
s  prednisolone,  which  has  been  substituted  by  prednisone
n  Mexican  studies,  for  reasons  of  availability.112 The  benefit
f  40  mg  daily  of  prednisolone  is  limited,  given  that  in  the
TOPAH  study  only  short-term  survival,  i.e.,  28  days,  was
mproved,  compared  with  monotherapy  with  pentoxifylline
r  placebo  and  with  the  concomitant  use  of  pentoxifylline-
rednisolone.  Unfortunately,  corticosteroids  have  no  effect
n  mortality  beyond  28  days.  Two  meta-analyses  that  include
esults  from  the  STOPAH  study,  confirmed  the  28-day  mor-
ality  benefit,  with  no  six-month  extension,  suggesting  the
eed  to  establish  new  clinical  objectives  and  new  thera-
eutic  strategies.113,114 There  is  a  risk  for  decompensating
ertain  conditions  after  starting  corticosteroid  therapy,  thus
he  contraindications  for  their  administration  must  be  taken
nto  account  (Table  4).  Infections,  which  are  a frequent
ause  of  death  in  AH,  are  an  extremely  important  con-
raindication.  Classically,  infection  control  before  beginning
reatment  with  a  steroid  has  been  suggested.  However,
here  is  evidence  of  similar  mortality  results  in  patients  with
p
w
a
c
o
3
r
f
s
g
i
t
t
u
t
t
t
3
c
a
i
s
i
i
c
w
l
i
q
s
i
fi
f
t
o
o
3The  Mexican  consensus  on  alcoholic  hepatitis  
AH  plus  active  infection  that  began  concomitant  antibiotic
and  steroid  therapy  vs.  AH  patients  with  no  infection.28,115
30  Intravenous  infusion  of  N-acetylcysteine  has  shown  an
increase  in  survival  in  the  short  term,  but  not  in  the  long
term  (three  to  six  months),  only  when  used  together  with
prednisolone.  Its  routine  use  is  not  recommended.
Quality  of  evidence:  C1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
N-acetylcysteine  has  been  suggested  as  a  therapeutic
option  because  its  mechanism  of  action  consists  of  increas-
ing  glutathione  reserves  to  reduce  the  oxidative  stress  that
is  a  cardinal  pathophysiologic  factor  in  patients  with  AH.
In  a  controlled  clinical  trial,  the  administration  of  pred-
nisolone  was  compared  with  its  concomitant  administration
with  intravenous  N-acetylcysteine  in  the  management  of
severe  AH.  Several  doses  and  infusion  speeds  were  utilized
for  N-acetylcysteine  on  the  first  day  of  administration  and
the  dose  of  100  mg  kg  of  body  weight  from  days  two  to  five.
There  was  a  significant  decrease  in  mortality  at  one  month
in  the  prednisolone  +  N-acetylcysteine  group  (8%),  compared
with  prednisolone  alone  (24%)  but  there  were  no  differences
in  relation  to  mortality  at  three  or  six  months.  In  a  sub-
analysis,  reduced  hepatorenal  syndrome-specific  mortality
at  six  months  and  infection  frequency  were  found.116,117
Despite  those  results,  more  evidence  is  needed  to  recom-
mend  its  routine  use,  given  that  there  is  still  no  improvement
in  the  overall  mortality  threshold  after  one  month.  Pred-
nisolone  is  not  available  in  Mexico,  but  the  replication  of
those  results  with  available  formulations  (prednisone)  could
be  viable.
31  There  is  no  current  scientific  evidence  that  pentoxi-
fylline  is  useful,  but  some  studies  have  shown  it  to  be
beneficial  for  reducing  the  risk  for  kidney  injury,  hepa-
torenal  syndrome,  and  death.
Quality  of  evidence:  C1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
Pentoxifylline  is  a  phosphodiesterase  inhibitor  that
suppresses  the  actions  of  tumor  necrosis  factor-alpha  (TNF-
alpha),  a  key  cytokine  in  the  pathophysiology  of  AH.118
One  of  the  first  promising  studies  was  conducted  by  Akriv-
iadis  et  al.  The  results  of  that  double-blind,  randomized
controlled  trial  on  patients  with  severe  AH  (MDF  score  >
32)  showed  that  treatment  with  pentoxifylline  improved
short-term  survival  and  that  the  benefit  appeared  to  be
related  to  a  significant  decrease  in  the  risk  for  the  devel-
opment  of  hepatorenal  syndrome.119 Nevertheless,  later
studies  have  not  shown  any  benefit  for  survival.  A  sys-
tematic  Cochrane  review  that  analyzed  five  clinical  trials
concluded  that  pentoxifylline  use  for  the  treatment  of
severe  AH  could  not  be  supported  or  rejected,  accord-
ing  to  the  available  evidence.120 Further  studies  explored
the  possibility  of  evaluating  whether  pentoxifylline  was  an
effective  additive  to  the  use  of  steroids  in  AH.  However,  a
randomized,  double-blind,  multicenter  study  that  included
23  hospitals  in  France  found  no  improvement  in  six-month
survival  with  the  combination  of  40  mg  daily  of  prednisolone345
lus  400  mg  of  pentoxifylline  three  times  a day  for  four
eeks.121 The  results  of  a  systematic  review  and  meta-
nalysis  that  included  a  total  of  2,639  patients  and  25  studies
onfirmed  that  pentoxifylline  as  monotherapy  had  no  effect
n  decreasing  mortality.122
2  Opportune  treatment  of  infections  is  essential  in  alco-
holic  hepatitis.
Quality  of  evidence:  A1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
In  patients  with  AH,  the  frequency  of  infections  is
eported  at  up  to  25%  of  cases,  increasing  the  rate  of  organ
ailure  and  death.123 In  the  STOPAH  study,  24%  of  deaths  were
econdary  to  infectious  events,  regardless  of  the  treatment
iven.81 Mortality  in  patients  with  infections  and  severe  AH
ncreases,  according  to  the  Lille  model,  even  in  responders
o  corticosteroid  therapy.124 Considering  that  one  of  the  con-
raindications  for  corticosteroid  therapy  is  the  presence  of
ncontrolled  infection  and  the  consequent  increase  in  mor-
ality  due  to  infections  in  patients  with  AH,  it  is  imperative
o  systematically  look  for  infections,  identify  them  oppor-
unely,  and  treat  them  in  those  patients.
3  Anti-TNF-alpha  biologic  agents  are  not  recommended  for
the  treatment  of  alcoholic  hepatitis.  Those  agents  are
associated  with  a high  risk  for  infections,  sepsis,  and
death.
Quality  of  evidence:  A1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
Despite  the  pathophysiologic  support  due  to  the  role  of
ertain  cytokines  in  AH,  such  as  TNF-alpha,  interleukin-1,
nd  interleukin-8,  current  evidence  is  not  consistent  regard-
ng  the  administration  of  anti-TNF  agents  in  patients  with
evere  AH.  A  systematic  review  conducted  in  2019  that
ncluded  the  analysis  of  five  studies  concluded  that  inflix-
mab  could  be  a  treatment  alternative  for  patients  in  whom
orticosteroids  were  contraindicated.  However,  the  review
as  based  on  case  series  and  two  clinical  trials.  From  the
atter,  the  use  of  three  doses  of  infliximab  was  shown  to
ncrease  the  risk  for  infection,  reaching  89%,  and  conse-
uently,  death.125 The  effect  of  the  combination  with  a
teroid  was  also  studied,  resulting  in  an  increased  risk  for
nfection  and  complications.  Even  though  apparent  bene-
ts  were  observed  in  the  reduction  of  biochemical  markers
or  inflammation  and  a  comparable  infection  rate  to  that  of
herapy  with  corticosteroids  alone  (10-20%),  the  routine  use
f  a  single  dose  of  infliximab  is  not  recommended  because
f  its  greater  adverse  effects  and  higher  treatment  cost.126
4  There  are  new  pharmacologic  agents  that  are  poten-
tially  beneficial  for  alcoholic  hepatitis.  The  gut-liver
axis,  hepatic  regeneration,  apoptosis,  oxidative  stress,
and  inflammatory  signaling  are  among  the  therapeutic
targets.Quality  of  evidence:  B1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
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Due  to  the  economic  burden  and  associated  mortality
f  AH,  clinical  trials  have  been  conducted  in  recent  years
o  evaluate  new  objectives  and  develop  viable  treatment
ptions  for  patients  with  severe  alcoholic  disease.  AH  is
ssociated  with  dysbiosis  of  the  gut  microbiota  due  to  alco-
ol  consumption,  resulting  in  the  gut-liver  axis  becoming
 potential  target  for  therapy.  AH-related  dysbiosis  has
een  shown  to  be  associated  with  an  increase  in  Bifidobac-
eria, Streptococci,  and  Enterobacteria,  with  a  decrease
n  Clostridium  leptum  or  Faecalibacterium  prausnitzii.127
here  is  evidence  that  supplementation  with  zinc  can  pre-
erve  intestinal  integrity,  reduce  hepatocytic  cell  death
y  restricting  the  pathway  mediated  by  Fas/FasL,  and
educe  oxidative  stress,  proinflammatory  cytokine  produc-
ion,  and  endotoxemia.  Zinc  is  generally  administered  at
 dose  of  220  mg  (50  mg  of  elemental  zinc  sulphate)  per
ay  with  food.128 Fecal  microbiota  transplant  has  also  been
roposed  as  a  treatment  option  in  AH.  A  pilot  study  on
atients  with  severe  AH  that  were  not  candidates  for  steroid
reatment  underwent  fecal  microbiota  transplant,  improv-
ng  the  outcome  scores  and  liver  disease  survival  at  one
ear.129 In  an  effort  to  increase  the  possibility  of  thera-
eutic  success,  studies  on  various  drug  combinations  have
een  conducted.  There  are  studies  that  have  utilized  the
ombination  of  an  interleukin-1  (IL-1)  receptor  antagonist,
alled  anakinra,  with  pentoxifylline  and  zinc,  and  other
tudies  have  evaluated  the  action  of  probiotics  and  bovine
olostrum  on  the  gut  microbiota  to  reduce  bacterial  translo-
ation.  Despite  promising  preliminary  results,  there  is  not
ufficient  solid  evidence  for  their  recommendation  in  AH.
ther  drugs  that  have  been  evaluated  as  anti-inflammatory
gents  that  are  different  from  anakinra,  are  obeticholic
cid,  cenicriviroc,  and  alopurinol  with  probenecid  but  there
re  still  no  satisfactory  results,  or  they  have  not  yet  been
ublished.101
5  The  use  of  granulocyte-colony  stimulating  factor  has
shown  improvement  in  liver  function  and  survival  in
patients  with  severe  alcoholic  hepatitis.  Its  routine  use
is  not  yet  recommended.
Quality  of  evidence:  B1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
Granulocyte-colony  stimulating  factor  (G-CSF)  is  a
ytokine  that  normally  acts  on  the  bone  marrow  microen-
ironment  to  stimulate  the  formation  of  blood  cells  and
here  are  several  commercial  presentations  of  the  factor
n  the  drug  market.130 A  randomized  study  on  a  small  sam-
le  of  patients  with  alcoholic  steatohepatitis  that  included
istologic  studies  evaluated  the  short-term  effects  of  G-
SF.  The  results  showed  that  a  five-day  course  of  G-CSF
timulated  hepatic  progenitor  cells  in  alcoholic  steatohep-
titis  patients  with  cirrhosis  and  moderate-to-severe  liver
ailure.  Those  effects  were  observed  seven  days  after  treat-
ent  was  begun,  due  to  the  fact  that  G-CSF  promoted  the
obilization  of  CD34+  cells  and  increased  the  hepatocyte
rowth  factor.131 Those  findings  have  also  been  documented
n  patients  treated  with  G-CSF  that  have  acute-on-chronic
iver  failure  of  alcoholic  etiology.132 A  randomized  study
l
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ublished  a  few  years  ago  reported  favorable  mortality
esults  utilizing  treatment  with  G-CSF  in  acute  alcoholic
epatitis.  In  that  clinical  trial,  subcutaneous  G-CSF  at  a  dose
f  5  g/kg  every  12  hours  for  five  days  increased  survival  to
0  days,  compared  with  standard  treatment  (p  =  0.001).133
-CSF  has  also  been  used  for  patients  that  are  nonresponders
o  steroids.  In  a  study  that  began  in  2015  and  is  projected
o  be  finished  in  2020  (ClinicalTrials.gov,  NCT02442180),
he  efficacy  of  G-CSF  is  being  evaluated  in  patients  with
evere  AH  that  have  had  a  partial  response  to  steroids  or
one  at  all.  The  randomized  study  is  named  GRACIAH  and
ts  hypothesis  is  that  said  therapy  can  aid  in  prolonging
urvival.134 Based  on  the  evidence  at  hand,  the  routine  use
f  G-CSF  is  not  presently  considered  in  all  patients  with
H.
6  Metadoxine  is  an  antioxidant  agent  that  can  be  used
as  adjuvant  therapy,  and  when  combined  with  corticos-
teroids,  has  shown  improvement  in  survival.
Quality  of  evidence:  B1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  95.5%  in  complete  agreement;  4.5%
n  complete  disagreement.
Metadoxine  is  a  compound  formed  by  in  vitro  crystal-
ization  of  two  molecules:  vitamin  B6 and  pyroglutamic
cid.135 It  is  an  antioxidant  drug  that  has  been  shown
n  experimental  models  to  prevent  glutathione  depletion
nd  the  increase  in  lipid  peroxidation  damage  caused
y  ethanol  and  acetaldehyde.  In  hepatic  stellate  cells,
t  prevents  the  increase  of  collagen  and  the  attenu-
ted  secretion  of  tumor  necrosis  factor-alpha  induced  by
cetaldehyde.136 In  addition  to  improving  glutathione  avail-
bility,  metadoxine  inhibits  hepatic  steatosis  in  patients
ith  AH.127
There  are  several  clinical  studies  on  the  use  of  metadox-
ne  in  liver  disease  associated  with  alcohol  consumption.  In  a
andomized  study  by  Mao  et  al.,  they  used  1,500  mg  of  meta-
oxine  daily  for  42  days  and  improvement  in  liver  function
ests  and  the  liver-spleen  ratio  evaluated  through  computed
omography  were  among  the  main  results.  Another  non-
andomized  study  reported  improvement  in  liver  function
nd  metabolism  with  a  dose  of  only  500  mg  daily  for  28
ays.  In  both  of  those  studies,  the  adverse  effects  were
inor.136
In  two  Mexican  studies  conducted  by  Higuera-de  la
ijera  et  al,  they  evaluated  the  effectiveness  of  meta-
oxine  in  patients  with  AH.  The  first  study  was  open  and
andomized,  and  its  aim  was  to  evaluate  the  effective-
ess  of  metadoxine  added  to  steroids  in  the  treatment
f  severe  AH.  One  group  received  prednisone  alone  at
0  mg  daily  (n  = 35)  and  another  group  received  prednisone
lus  1,500  mg  of  oral  metadoxine  daily  (n  =  35),  for  30
ays.  Survival  was  evaluated  at  30  and  90  days.  The  main
esults  were  better  survival  at  30  days  (74.3%  vs.  45.7%,
 = 0.02)  and  at  90  days  (68.6%  vs.  20%,  p =  0.0001)  and
ess  development  or  progression  of  encephalopathy  and
epatorenal  syndrome  in  the  group  that  received  meta-
oxine.  There  was  also  greater  response  to  steroids  in
he  metadoxine  group.137 The  second  study  was  open  and
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randomized,  and  unlike  the  first,  it  was  conducted  on
four  groups.  Group  1  (n  =  35)  received  40  mg/day  of  pred-
nisone,  group  2  (n  =  35)  received  500  mg  three  times  a
day  of  prednisone  +  metadoxine,  group  3  (n  =  33)  received
400  mg  three  times  a  day  of  pentoxifylline,  and  group  4
(n  =  32)  received  500  mg  three  times  a  day  of  pentoxi-
fylline  +  metadoxine.  Treatment  duration  was  30  days  in  all
the  groups.  The  results  showed  that  metadoxine  improved
the  three  and  six-month  survival  rates  in  patients  with
severe  AH.  Alcohol  abstinence  is  a  key  factor  for  survival
in  those  patients,  and  the  patients  that  received  the  ther-
apy  combined  with  metadoxine  were  more  likely  to  maintain
abstinence  than  those  that  received  monotherapy  with  pred-
nisone  or  pentoxifylline.138
Based  on  the  results  of  the  abovementioned  studies  on
Mexican  patients,  oral  metadoxine  at  a  dose  of  1,500  mg
daily  is  an  antioxidant  agent  that  can  be  considered  addi-
tional  treatment  in  patients  with  AH.
37  Liver  transplantation  can  be  considered  a  therapeutic
option  in  selected  cases  of  severe  alcoholic  hepatitis.
Quality  of  evidence:  A1.
Strength  of  recommendation:  strong,  in  favor  of.
Agreement  reached:  100%  in  complete  agreement.
The  selection  of  candidates  for  liver  transplantation
is  always  a  great  responsibility  for  the  professionals  that
perform  it.  One  of  the  main  points  against  the  use  of
liver  transplantation  for  selected  cases  of  AH  is  outcome,
given  the  severity  of  the  disease.  Nevertheless,  psychosocial
aspects  have  always  played  an  essential  role  in  decision-
making  related  to  liver  transplantation  in  ALD  due  to  the
risk  for  alcohol  relapse  that  would  go  against  the  basic  prin-
cipal  of  any  treatment  of  AH.  ALD  is  currently  the  most
common  reason  for  liver  transplantation,  with  similar  out-
comes  at  one  and  five  years  to  those  of  other  indications.
The  use  of  tools  for  predicting  the  risk  for  alcohol  relapse
is  inaccurate,  including  the  six-month  alcohol  abstinence
rule.  In  addition,  there  is  the  virtual  risk  that  if  intense
liver  transplantation  screening  is  eliminated,  extending  its
indiscriminate  use  for  ALD,  it  would  result  in  a  smaller  num-
ber  of  donors  than  patients  requiring  liver  transplant.139,140
Nevertheless,  there  are  other  considerations  with  respect  to
abstinence  duration.  Regarding  the  addition  of  patients  with
AH  to  the  liver  transplantation  waiting  list,  three  months
of  alcohol  abstinence  might  be  better  than  six  months.
Patients  that  lack  social  support,  are  active  smokers,  have
psychotic  or  personality  disorders,  or  a  pattern  of  noncom-
pliance  should  be  added  to  the  waiting  list  with  reservations.
Patients  diagnosed  with  alcohol  abuse  rather  than  alcohol
dependency  can  be  better  candidates.  Patients  that  have
regular  addiction  treatment  appointments  with  a  psychi-
atrist  or  psychologist  also  appear  to  have  more  favorable
behavior.140
Thus,  liver  transplantation  is  currently  a  treatment
indication  for  severe  AH  (MDF  score  >  32),  in  patients
that  are  nonresponders  to  (Lille  model  >  0.45)  or  not
eligible  for  corticosteroids,  patients  in  their  first  hep-
atic  decompensation  event,  and  patients  with  a  favorable
psychosocial  profile  and  social  support.  Transplantation
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xclusion  criteria  are:  uncontrolled  infection,  comorbid  sys-
emic  disease  that  impedes  recovery,  poor  prognostic  profile
n  relation  to  alcohol  use,  lack  of  social  support,  previous
iver  decompensation  events,  and  uncontrolled  psychiatric
omorbidity.139
With  respect  to  survival  and  the  alcohol  relapse  rate
n  patients  transplanted  due  to  acute  AH  that  did  not
omply  with  six  months  of  alcohol  abstinence,  a  2018  meta-
nalysis  concluded  that  early  liver  transplantation  is  a
ife-saving  treatment  in  patients  with  medical  treatment-
efractory  AH  and  with  no  increased  possibility  of  alcohol
elapse  after  transplantation,  in  well  selected  patients.141
n  another  recent  meta-analysis  that  analyzed  11  studies
o  review  the  available  evidence  on  liver  transplantation
n  patients  with  AH  and  evaluate  alcohol  relapse  and  sur-
ival  at  six  months,  utilizing  strict  selection  criteria,  those
uthors  found  that  14%  of  the  patients  with  severe  AH  had
lcohol  relapse  after  liver  transplantation.  The  percent-
ge  of  alcohol  relapse  in  the  transplanted  patients  with  AH
as  similar  to  that  of  the  patients  with  alcoholic  cirrho-
is  that  underwent  elective  liver  transplantation.142 Other
ncouraging  survival  data  are  described  in  the  study  by
ee  et  al.  According  to  a  retrospective  analysis  of  147
atients  that  underwent  early  liver  transplantation  (before
ix  months  of  abstinence)  due  to  severe  AH,  they  found
hat  the  majority  of  patients  had  one-year  (94%)  and  three-
ear  (84%)  survival,  which  was  similar  to  that  of  patients
hat  received  liver  transplantations  for  other  indications.
hose  authors  also  emphasized  the  fact  that  sustained  alco-
ol  consumption  after  transplantation  was  infrequent,  but
hen  it  occurred,  it  was  associated  with  a higher  mortality
ate.143
In  the  context  of  decision  delay  or  in  candidates  on  the
ransplantation  waiting  list,  the  MARS  therapy  has  shown
ufficient  improvement  in  the  biochemical  profile  as  bridging
herapy.  However,  improvement  in  short-term  or  long-term
ortality  has  not  been  demonstrated.144
onclusions
evere  AH  is  an  entity  with  a  high  mortality  rate.  This  is
he  first  Mexican  consensus  on  AH  that  addresses  definitions
f  alcohol  use  disorders  and  the  diagnosis  and  treatment
f  AH  formulated  in  37  recommendations.  Importantly,  AH
s  a  condition  that  ranges  from  an  asymptomatic  status
o  the  maximum  expression  of  liver  failure.  Severe  AH  is
efined  by  a  Maddrey’s  discriminant  function  score  ≥  32
r  a  MELD  score  equal  to  or  above  21.  There  is  no  spe-
ific  biomarker  for  its  diagnosis  and  so  it  is  important  to
e  supported  by  laboratory  tests.  With  respect  to  treat-
ent,  alcohol  abstinence  continues  to  be  essential  and
utritional  support  is  important.  Steroids  are  a  therapeutic
ption  in  severe  AH.  The  use  of  antioxidants,  such  as  meta-
oxine  combined  with  steroids,  has  been  shown  to  increaseatients.  There  are  new  potentially  beneficial  drugs  for  AH
ut  there  is  still  no  evidence  for  their  use  in  daily  clinical
ractice.
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